RT Journal Article
SR Electronic
T1 Predicting Age-Related Macular Degeneration Progression with Contrastive Attention and Time-Aware LSTM
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.19.22275305
DO 10.1101/2022.05.19.22275305
A1 Changchang Yin
A1 Sayoko E. Moroi
A1 Ping Zhang
YR 2022
UL http://medrxiv.org/content/early/2022/05/21/2022.05.19.22275305.abstract
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in developed countries. Identifying patients at high risk of progression to late AMD, the sight-threatening stage, is critical for clinical actions, including medical interventions and timely monitoring. Recently, deep-learning-based models have been developed and achieved superior performance for late AMD prediction. However, most existing methods are limited to the color fundus photography (CFP) from the last ophthalmic visit and do not include the longitudinal CFP history and AMD progression during the previous years’ visits. Patients in different AMD subphenotypes might have various speeds of progression in different stages of AMD disease. Capturing the progression information during the previous years’ visits might be useful for the prediction of AMD progression. In this work, we propose a Contrastive-Attention-based Time-aware Long Short-Term Memory network (CAT-LSTM) to predict AMD progression. First, we adopt a convolutional neural network (CNN) model with a contrastive attention module (CA) to extract abnormal features from CFPs. Then we utilize a time-aware LSTM (T-LSTM) to model the patients’ history and consider the AMD progression information. The combination of disease progression, genotype information, demographics, and CFP features are sent to T-LSTM. Moreover, we leverage an auto-encoder to represent temporal CFP sequences as fixed-size vectors and adopt k-means to cluster them into subphenotypes. We evaluate the proposed model based on real-world datasets, and the results show that the proposed model could achieve 0.925 on area under the receiver operating characteristic (AUROC) for 5-year late-AMD prediction and outperforms the state-of-the-art methods by more than 3%, which demonstrates the effectiveness of the proposed CAT-LSTM. After analyzing patient representation learned by an auto-encoder, we identify 3 novel subphenotypes of AMD patients with different characteristics and progression rates to late AMD, paving the way for improved personalization of AMD management. The code of CAT-LSTM can be found at GitHub1.CCS CONCEPTS • Applied computing → Health informatics; • Computing methodologies → Neural networks.ACM Reference Format Changchang Yin, Sayoko E. Moroi, and Ping Zhang. 2018. Predicting Age-Related Macular Degeneration Progression with Contrastive Attention and Time-Aware LSTM. In Proceedings of SIGKDD 2022. ACM, New York, NY, USA, 11 pages. https://doi.org/10.1145/1122445.1122456Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.ncbi.nlm.nih.%20gov/projects/gap/cgi-bin/study.cgi?study_id=phs000001.v3.p1I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the study are available online at https://www.ncbi.nlm.nih.%20gov/projects/gap/cgi-bin/study.cgi?study_id=phs000001.v3.p1